Semaglutide is a medication in the class of GLP-1 (glucagon-like peptide-1) receptor agonists. Originally developed to help manage type 2 diabetes by regulating blood sugar levels, it works by mimicking a naturally occurring hormone that stimulates insulin production, reduces glucose release from the liver, and slows digestion. These actions help control blood sugar and improve metabolic function.

In addition to managing diabetes, semaglutide has been shown to aid in weight management by promoting satiety, reducing appetite, and curbing cravings. It also demonstrates benefits for cardiovascular health and reducing inflammation. Recently, semaglutide has gained interest for its potential to support longevity by enhancing metabolic efficiency, reducing chronic disease risks, and improving long-term health outcomes.

Microdosing semaglutide refers to taking lower doses of the medication, primarily to support long-term health and longevity, rather than for diabetes or weight management. As a GLP-1 receptor agonist, semaglutide mimics a natural hormone that regulates appetite, insulin, and inflammation. When microdosed, it may help reduce chronic inflammation, enhance metabolic function, and improve cardiovascular health—key factors for aging well and maintaining vitality over time.

Although microdosing semaglutide is not meant for significant weight loss, it may reduce appetite and cravings, leading to gradual, sustained weight management. However, the primary focus is on supporting longevity by promoting overall metabolic health, lowering the risk of chronic diseases, and improving resilience as you age. Always consult with a healthcare professional to determine if microdosing semaglutide aligns with your health goals.

Please be advised that microdosing tirzepatide for off-label use as a longevity product does not have a BMI requirement at this time. This differs from our weight management product, which requires a BMI of 28 or higher.

Before starting any treatment, including the off-label use of tirzepatide, it is critical to consult with a qualified healthcare provider. Tirzepatide is associated with certain contraindications, which include, but are not limited to:

• • Personal or Family History of Medullary Thyroid Carcinoma (MTC): Semaglutide may increase the risk of thyroid C-cell tumors in individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Hypersensitivity: It is contraindicated in patients with known hypersensitivity to semaglutide or any of its components, as it may cause allergic reactions, including anaphylaxis or angioedema.
  • Pregnancy: Semaglutide is not recommended during pregnancy due to limited safety data, and it should be discontinued at least two months before a planned pregnancy.
  • Diabetic Ketoacidosis (DKA): Semaglutide should not be used to treat type 1 diabetes or DKA.

EllieMD compounds semaglutide and tirzepatide with Vitamin B12 (cyanocobalamin). This metabolic support ingredient is added to enhance the overall benefits of the treatment. Vitamin B12 plays a critical role in energy metabolism and supports patients’ overall health, making the compounded formulation unique compared to commercially available options. These compounds are prepared in compliance with Section 503A of the Federal Food, Drug, and Cosmetic Act to address specific patient needs and provide personalized care solutions.

EllieMD partners with a pharmacy that operates in compliance with Section 503A of the Federal Food, Drug, and Cosmetic Act. This allows for the compounding of medications like semaglutide and tirzepatide when specific formulations are required that are not commercially available. These compounds may address unique patient needs, such as customized dosing, alternative delivery methods, or sensitivities to standard ingredients. By adding Vitamin B12, EllieMD ensures the compounded medications meet both clinical efficacy and personalized patient care standards.

• Pancreatitis: Reports of acute pancreatitis exist; discontinue use if pancreatitis is suspected.
• Gallbladder Disease: Semaglutide may increase the risk of gallstones and gallbladder disease.
• Renal Impairment: There have been reports of acute kidney injury, especially in those with pre-existing kidney issues or dehydration.
• Diabetic Retinopathy: Semaglutide may exacerbate retinopathy, so patients with a history of this condition should be closely monitored.
• Hypoglycemia: When used with insulin or sulfonylureas, there is a higher risk of hypoglycemia, necessitating dose adjustments.
• Gastrointestinal Issues: Common side effects include nausea, vomiting, diarrhea, and constipation, so caution is advised for those with severe GI diseases.

Microdosing semaglutide is primarily a longevity product and not intended as a dedicated weight management solution. For significant weight loss (more than 5-10 lbs), we recommend our weight management product. However, while the focus of microdosing is on long-term health and aging, it can help reduce appetite, curb cravings, and promote gradual, sustained weight loss for those aiming to maintain a healthy weight.

Individuals who may benefit from microdosing semaglutide for longevity include:

• • Those with Metabolic Concerns: Semaglutide can help individuals with insulin resistance, prediabetes, or mild blood sugar issues by stabilizing glucose levels and improving insulin sensitivity.
  • Promoting Sustained Weight Loss: While microdosing is not intended for significant weight loss, it can assist in reducing appetite and promoting gradual, sustained weight loss, which aligns with its primary goal of supporting long-term health and longevity.
  • Cardiovascular Health: People at risk for cardiovascular diseases may benefit from semaglutide’s potential to reduce blood pressure, improve cholesterol, and decrease inflammation.
  • Preventative Health: Those focused on proactive aging may incorporate microdosing into a broader longevity strategy aimed at maintaining metabolic health and reducing age-related risks.
  • Neuroprotection: Emerging evidence suggests that GLP-1 receptor agonists like semaglutide may have neuroprotective benefits, appealing to those aiming to protect cognitive function as they age.

The recommended off-label longevity protocol for microdosing semaglutide is 0.25 mg per week. 

You will receive a vial containing 5 mg of semaglutide (the concentration and vial size may vary by pharmacy). If taken at the recommended dose of 0.25 mg per week, the medication should last at least 12 weeks.

Yes! Your prescription will include alcohol wipes, syringes, and everything you need to get started on your wellness journey.

Yes, while a medical professional will review your profile before prescribing semaglutide, it’s crucial to consult your primary care provider, who is familiar with your full medical history, to ensure comprehensive and personalized care. Your doctor can provide insights into your overall health that might not be available through our service.

When comparing the potential longevity benefits of microdosing semaglutide and tirzepatide, both medications offer overlapping health improvements due to their action on GLP-1 receptors. However, tirzepatide also activates GIP (glucose-dependent insulinotropic polypeptide) receptors, which may offer additional advantages. Here’s a breakdown of how these two medications compare in terms of longevity-related benefits:

• Metabolic Health:
  • Both semaglutide and tirzepatide improve insulin sensitivity, stabilize blood sugar levels, and reduce the risk of developing type 2 diabetes. These actions help protect against metabolic disorders, which are linked to aging-related diseases like cardiovascular conditions, obesity, and neurodegeneration.
• Cardiovascular Health:
  • Both drugs are effective in reducing risk factors for cardiovascular disease, such as lowering blood pressure, improving cholesterol levels, and aiding in weight management. Cardiovascular health is a key component of longevity, and reducing risks of heart attacks and strokes is crucial for a longer, healthier life.
• Inflammation Reduction:
  • Chronic low-grade inflammation contributes to aging and is a major risk factor for diseases like Alzheimer’s, diabetes, and cardiovascular disease. Both medications exhibit anti-inflammatory effects, which are important in reducing the systemic inflammation linked to accelerated aging.
• Weight Management:
  • Semaglutide and tirzepatide both promote satiety and reduce appetite, leading to gradual and sustained weight loss. Maintaining a healthy weight is crucial for reducing the risks of many age-related diseases, including diabetes, heart disease, and some cancers.
• Neuroprotective Potential:
  • GLP-1 receptor agonists, including both semaglutide and tirzepatide, show early promise in providing neuroprotective benefits, potentially lowering the risks of neurodegenerative diseases like Alzheimer’s by reducing oxidative stress and inflammation in the brain.

Unique Potential Benefits of Tirzepatide:

• Dual GIP/GLP-1 Receptor Agonism:
  • Tirzepatide’s unique mechanism of action as a dual agonist (GIP and GLP-1) may offer additional benefits over semaglutide. GIP may improve fat metabolism, reduce adiposity (fat accumulation), and provide a stronger impact on insulin sensitivity and glucose regulation. These effects could offer a more comprehensive approach to metabolic health, which is key to longevity.
• Enhanced Weight Loss:
  • Clinical trials have shown that tirzepatide can induce more significant weight loss compared to semaglutide. Since excess weight is a major risk factor for many chronic conditions, tirzepatide’s superior ability to promote weight reduction may enhance longevity more effectively in those who are overweight or obese.
• Greater Impact on Glucose Control:
  • Tirzepatide appears to have a more pronounced effect on improving glucose control compared to semaglutide, which could make it a more powerful tool for preventing insulin resistance and type 2 diabetes—both significant factors in age-related health decline.

Key Considerations for Longevity:

• Semaglutide is well-studied for its effects on metabolic health, weight management, cardiovascular health, and inflammation reduction. It offers a strong foundation for longevity, especially for those primarily looking to stabilize metabolic function and improve cardiovascular health.
• Tirzepatide, with its dual action on both GIP and GLP-1 receptors, may provide additional advantages in fat metabolism, insulin sensitivity, and weight loss. These factors make it potentially more effective for people who have more pronounced metabolic concerns or are at higher risk for obesity-related diseases.

This information is for educational purposes and not intended as medical advice. Microdosing semaglutide is not FDA-approved for longevity purposes, and its long-term effects are still being studied. Always consult with a licensed healthcare professional before starting any treatment. Individual results may vary.